iBio, Inc. entered into an Open Market Sale AgreementSM (ATM Agreement) with Jefferies LLC on February 27, 2026. This agreement allows iBio to sell up to $100,000,000 of its common stock from time to time through Jefferies in an at-the-market offering. Sales will be made pursuant to a shelf registration statement on Form S-3 (File No. 333-293864), filed on February 27, 2026, once declared effective. iBio will pay Jefferies a commission of up to 3.0% of the gross proceeds from sales. The company also agreed to reimburse Jefferies for certain expenses, including counsel fees up to $100,000, plus additional fees for certain SEC filings. On February 23, 2026, iBio terminated its prior At Market Issuance Sales Agreement, dated July 3, 2024, with Chardan Capital Markets, LLC and Craig-Hallum Capital Group LLC, which had an aggregate offering price of up to $7,350,000.